A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Xeris Biopharma Holdings, Inc. XERS
Mixed broader-coverage candidate · Xeris Biopharma Holdings, Inc.
On FrontierLab's discovery record since 2026-07-15 (11 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Mixed" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-10-02), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 36.3% |
|---|---|
| Gross margin | 83.3% |
| Gross profits / assets | 0.68 |
| Rule of 40 | 47.2 |
| Net margin | 10.9% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 4.8 |
Quality checklist
- ✓ Revenue growth — 36.3% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.68 (pass ≥ 0.33)
- ✓ Gross margin — 83.3% (pass ≥ 60%)
- ✓ Cash generation
- ✗ Share dilution — 10.8%
Fundamentals — snapshot as of 2026-10-02
| Stage | Established |
|---|---|
| Share issuance (YoY) | 10.8% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-0.10 |
| Burn multiple | — |
| Gross-margin trend (pts) | 2.2 |
| Cash / assets | 0.3 |
| Net debt / EBITDA | 10.2 |
| Statements as of | Q2 FY2026 · filed 2026-08-06 |
Momentum context — a snapshot from 2026-10-02, not current
| Price at surface | $9.25 (as of 2026-10-02) |
|---|---|
| 52-week range | $5.25 – $11.33 |
| % off 52-wk high | -18.4% |
| RSI (14) | 59 |
| Relative volume | 0.9× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-10-02 (end-of-day). How grades are computed →